Full-Time
Posted on 3/16/2025
Develops medicines for serious diseases
No salary listed
Senior, Expert
Company Does Not Provide H1B Sponsorship
Boston, MA, USA
This is a hybrid role working 3 days on-site and up to two days remotely.
Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.
We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.
NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).